RxDoctor Payments Data

Theodore Lawler, MD

Family Medicine · Houston, TXNPI 1144208414

Payments from drug & device makers

$1,267in general payments, 2019–2025

Across 80 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$312
  • Novo Nordisk$277
  • AstraZeneca$235
  • Astellas Pharma US Inc$198
  • Exact Sciences$44
  • Merck$43
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$1,267100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,267 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$92,715
Medicare patients
121
Services billed
2,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$161,992
EliquisApixaban99$118,942
JanuviaSitagliptin Phosphate61$81,438
FarxigaDapagliflozin Propanediol64$74,898
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$70,656
XareltoRivaroxaban36$51,308
JardianceEmpagliflozin32$41,797
Tresiba Flextouch U-200Insulin Degludec30$40,462
TradjentaLinagliptin35$39,381
TrulicityDulaglutide17$22,951
Olmesartan Medoxomil624$22,093
Atorvastatin Calcium2,013$18,153
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$17,230
Soliqua 100-33Insulin Glargine/Lixisenatide17$17,135
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$16,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$277$161,992117 claims
PfizerEliquis$34$118,94299 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$312$96,906125 claims
MerckJanuvia$43$81,43861 claims
AstraZenecaFarxiga$235$74,89864 claims
Lilly USA, LLCTrulicity$31$22,95117 claims
Astellas Pharma US IncMyrbetriq$198$14,38418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →